DFTX

Definium Therapeutics, Inc.

BS score 21.6LOWPHASE3 · mkt cap $2.14B · rev ttm $0

drug hypothesis

MM120 (LSD D-Tartrate) modulates 5-HT2A serotonin receptor (and other serotonin receptors) to treat Generalized Anxiety Disorder (Anxiety Symptoms).

moa:MM120 is a synthetic lysergic acid derivative that acts as a potent agonist at serotonin 5-HT2A receptors, producing psychedelic effects thought to induce anxiolytic benefits through potential neuroplasticity or acute psychedelic experience followed by sustained symptom relief.

score breakdown

trial design0

base rate disconnect14

language red flags80

composite21.6

valuation analysis

market cap$2.14B

revenue ttm$0

phasePHASE3

historical base rate30%

disconnect ratio0.5x

lead trialNCT06809595

meta

cik0001813814

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 2 randomized, quadruple-blind, placebo-controlled dose-finding study enrolling 198 patients with generalized anxiety, evaluating multiple dose levels of MM120 with primary endpoint of dose response at 4 weeks and extensive secondary endpoints including HAM-A, MADRS, CGI-S/I, PGI-S/C, SDS, EQ-5D-5L, PSQI, and ASEX scales through 12 weeks

primary endpoint:Dose Response at 4 weeks

claimed differentiation

NOT PROVIDED - SEC filing business section appears truncated/incomplete in source material

language red flags

SEC filing business section not provided - unable to assess claimed differentiation, risks, or corporate language
No preclinical evidence provided in source material to support efficacy claims
Trial completed October 2023 but outcome data not visible in provided information
Heavy reliance on psychedelic mechanism with inherent regulatory and safety hurdles not addressed in available data